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Objectives: Retrospective study of oncology patients with cardiovascular event, in 
order to help an decision. There is evidence regarding the prognosis of cancer patients, 
which is seen as a carrier of a chronic disease that throughout its evolution may have 
acute decompensation, as cardiovascular manifestations. Progress in cancer treatment 
also resulted in increased exposure of patients to cardiovascular risk factors and chemo-
therapy with potential cardiotoxicity and sure for expenses in terms of adding costs of 
care. MethOds: We analised 68 cases collected and registered by the time of cardiology 
and oncology audit, in 2012. Outocmes items used: Costs, cardiovascular events associ-
ated with cancer. Results: Among 68 cases, Breast Cancer is the majority account-
ing 32 ( 47% ). All of them were seen by cardiologist and the total amount spent were 
US$15.000,00 . Thirty one patients were caracterized having a cardio - vascular event 
and the costs were comprise by echocardio, ergo-cardio test, angio tomography and 
coronary cardiac catheterization. The costs of oncology treatment range from $1.500,00 
to $ 6.800,00 USD per cicle, each 21 or 28 days, that means $18.000,00 to $ 120.000,00 USD a 
year . It means that the provisional budget will range from $ 1.224.000,00 to $ 8.160.000,00 
USD a year for the cohort of 68 patients in our institution. So, we will spend 0.18 % to 
1.22 % in cardiac vigilance for the oncologic patients describe above. cOnclusiOns: 
The costs still low, the price of the oncologic cure with an cardiologic event needs more 
studies, details need for further recomendations.
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ObjectivOs: La “Change Pain Survey at EFIC 2009- Physian’s perception on manage-
ment of severe chronic non-cancer pain” realizada en países europeos, confirma la 
falta de conocimiento para el dolor neuropático y las variedades de enfoques del 
tratamiento del dolor crónico sin utilizar una guía consistentemente. Aplicando la 
misma encuesta a médicos generales y especialistas en países de América Latina, 
se exploró la percepción y comprensión de la forma de manejo del dolor crónico en 
América Latina. MetOdOlOgíAs: Se realizaron 2130 encuestas vía electrónica de 
octubre 2012 a marzo 2013, en forma aleatoria a médicos generales y especialistas a 
través de sociedades médicas, fuerza de ventas o aplicadas en congresos médicos de 
15 países de América Latina, poniendo énfasis en la percepción del tipo de dolor para 
elección del tratamiento. ResultAdOs: El porcentaje por especialidad fue: 18% trau-
matólogos, 12% médicos generales, 12% de rehabilitación, 13% anestesiólogos, 10% 
algólogos, y otras especialidades menores a 5%. Clasifican el dolor crónico muy heter-
ogéneamente, desde nivel 4 al 9, en una escala del 1-10. Sus objetivos del tratamiento 
del dolor son reducción del dolor (30%) y calidad de vida (27%). La elección terapéutica 
para el dolor la deciden por eficacia (19.28%), tolerabilidad (21.83%), eficacia/equilibrio 
de efectos adversos (24.69), calidad de vida (18.19%) y costo (15.99%). Perciben un cono-
cimiento limitado de las opciones terapéuticas y sobre la diferencia fisiológica entre 
dolor nociceptivo y dolor neuropático. cOnclusiOnes: La encuesta muestra una 
ausencia de estandarización en el tratamiento de dolor crónico y desconocimiento 
de las opciones terapéuticas ideales para el dolor crónico. Existe una necesidad de 
contar con un mejor conocimiento sobre el dolor crónico para lograr un adecuado 
manejo multimodal para su seguimiento y control.
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Objectives: Cuadro Básico is a list of minimum medicines needed for a basic health 
care system, listing the most efficacious, safety and cost-effective medicines for pri-
ority conditions. The importance is to ensure availability of drugs for current and 
future public health relevant diseases. The objective is to describe the characteris-
tics of National List in Mexico and compare it with the Instituto Mexicano Seguro 
Social (IMSS) List in order to hypothesize the relevance of the drugs included on 
both Lists versus current and future health needs in the country. MethOds: It was 
performed a descriptive analysis of the two lists organized by therapeutic area. The 
description includes number of total codes, and number per therapeutic area. The 
information was compared to find the gaps on the number of codes between the two 
Lists. In addition it was identified the top health priorities and prevalence. Results: 
National list has 1631 codes; the therapeutic areas with the majority of codes are 
infectious diseases (222) and Oncology (150). IMSS List has 1145 codes. The biggest 
relative difference between the two lists come from codes available for neurology, 
dermatology and ophthalmology; 57%, 56% and 45% codes are not available at IMSS, 
respectively. The top mortality causes in Mexico are heart disease, diabetes, cancer, 
accidents, liver diseases, stroke and COPD. If the analysis is made by disease, it worth 
mention that COPD only have 3 codes at IMSS and 7 codes at National Listing, while 
Alzheimer disease do not have any code at IMSS. cOnclusiOns: A more extensive 
analysis (already available) brings information about the gaps between health needs 
and the drugs available. Mexico has an increased number of an aging population, 
which requires access to different drugs. The Essential list of WHO has 315 compounds 
versus Mexican which has 1631 codes. Is it a good guideline for decision makers?
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(CE) analysis to estimate the impact of this pricing policy on the CE of trastuzumab 
in Latin-America (LA). MethOds: Model structure and a common methodology 
for identifying costs and resource use were agreed with country teams. A Markov 
model was designed to evaluate life years (LY), quality adjusted life years (QALYs) 
and costs from a health care sector perspective. A systematic search on effectiveness, 
local epidemiology and costs studies was undertaken to populate the model. A base 
case scenario using transition probabilities from trastuzumab clinical trials, and two 
alternative scenarios with transition probabilities adjusted to reflect breast cancer 
epidemiology in each country, were built to better fit local cancer prognosis. Results: 
Incremental discounted benefits and costs of the trastuzumab strategy ranged from 
0·87 to 1·00 LY, 0·51 to 0·60 QALY and $24,683 to $60,835 (2012 US dollars). Incremental 
CE ratios ranged from $42,104 to $110,283 per QALY, equivalent to 3·6 gross domestic 
products per capita (GDPc) per QALY in Uruguay to up to 35·5 GDPc per QALY in Bolivia. 
The probabilistic sensitivity analysis showed a 0% probability that trastuzumab is CE 
if the willingness-to-pay (WTP) threshold is one GDPpc per QALY, and remains 0% at a 
WTP threshold of three GDPc except in Chile and Uruguay (probability 4·3% and 26·6% 
respectively). cOnclusiOns: Despite its proven CE in other settings, trastuzumab 
was not CE in LA at its current price. Better cooperation between the public and pri-
vate sectors is still needed to make innovative drugs available and affordable in DC.
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Objectives: To estimate national expenditure with procedures of the National 
Cervical Cancer Control Program. MethOds: A cost description study was con-
ducted to develop estimates of expenditures related to care held under the National 
Cervical Cancer Control Program in Brazil. Health Information Systems of the Public 
Health System, SUS (SIH, SIA, APAC, SIAB, and SIGTAP SISCOLO), national survey 
(PNAD 2008), and guidelines of INCA / MS, and reference systems for payments of the 
private system were consulted to construct estimates of direct and indirect costs. 
The estimates were grouped by sets of procedures of the stages of cervical cancer 
care (screening, diagnosis, treatment of precancerous lesions of the cervix - CIN I 
and CIN II / III and treatment of cervical cancer). The study was conducted from the 
perspectives of the health care system and society. Results: The total direct cost 
of SUS in 2006 was estimated at R$ 227,167,515, ambulatory visits were responsible 
for 27% of spending. Screening represented the highest spending. The estimated 
total direct spending to the private sector in 2006 was R$ 938,707,221, ambulatory 
visits were responsible for 68% of spending. The transport costs were estimated at 
R$ 230,533,910. Lost productivity was based on the human capital approach and 
was estimated at R$ 1,463,977,777. The final value of the direct and indirect costs 
estimated and adjusted for the year 2008 was R$ 3,193,335,402. cOnclusiOns: 
Spending with National Cervical Cancer Control Program is very significant. There 
is need for more costing studies in the country, alongside a greater structuring of 
official systems cost data available in order to contribute to the standardization and 
accuracy of the estimates of national costs.
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ObjectivOs: Evaluar la costo-efectividad de estrategias de prevención primaria 
(vacunación) y secundaria (tamización) para la prevención del cáncer de cuello 
uterino en Colombia. MetOdOlOgíAs: Un modelo de Markov de la historia natural 
del cáncer de cuello uterino fue desarrollado para evaluar las siguientes estrategias: 
no tamización, tamización (citología convencional y en base líquida, pruebas ADN 
VPH, pruebas rápidas de ADN VPH y via vili), vacunación y tamización + vacunación. 
Las estrategias se evaluaron solas o combinadas, para un total de 32 estrategias evalu-
adas. Los años de vida ganados (AVG) fueron usados como medida de efectividad. El 
estudio tuvo la perspectiva del tercero pagador, solo se incluyeron costos directos. 
Se calcularon razones de costo-efectividad y costo-efectividad incremental, se con-
dujeron análisis de sensibilidad determinísticos y probabilísticos. Se aplicó tasa de 
descuento del 3% a los costos y resultados en salud. ResultAdOs: Las estrategias 
que quedaron sobre la frontera eficiente fueron: la vacunación, la vacunación más 
las pruebas rápidas de ADN VPH cada 10 años desde los 35 - 50 años, la vacunación 
más la prueba de ADN VPH cada 3 años desde los 30-69 años con triage (via vili) y sin 
triage de las mujeres positivas a la prueba y la vacunación más la citología en base 
líquida en el esquema 1-1-1-3 desde 25-69 años. El costo por año de vida ganado para 
las estrategias arriba mencionadas fue de $US 1.288, $US 6.447, $ US 8.875, $US 14.186 
y $US 94.503 respectivamente. El análisis probabilístico mostró que para umbrales de 
disponibilidad a pagar superiores a $US 13.000 la tamización con prueba de ADN-VPH 
cada 3 años más vacunación es la estrategia más costo-efectiva. cOnclusiOnes: 
La tamización con prueba ADN-VPH cada 3 años más vacunación en mujeres de 12 
años sería una alternativa costo-efectiva para Colombia.
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